Aarti Pharmalabs Limited — Q4 FY25 earnings call

Call held 12 May 2025

Management summary

Aarti Pharmalabs delivered a strong FY25 with significant growth in revenue, EBITDA, and PAT, driven by robust performance across all segments. The company is progressing with key capacity expansions in Xanthine and Atali, though the Atali project timeline has been adjusted. Sustainability efforts were recognized, and the company provided positive guidance for FY26, despite some short-term impacts on the Ganesh Polychem business.

Highlights

  • Revenue for FY25 stood at Rs. 2,113 crores, a 14% increase YoY, reflecting an upward growth trajectory.

  • EBITDA for FY25 reached Rs. 464 crores, growing by 20% YoY, with Q4 EBITDA margins expanding to 26% from 23% in Q4 FY24.

  • Profit after tax for FY25 reached Rs. 272 crores, a 26% increase over FY24, driven by topline growth and margin expansion.

  • The CDMO/CMO segment saw an increase in active projects to 61 (from 56), with 33 projects at the commercial stage.

  • The company earned an EcoVadis Gold Rating and SBTi approval for GHG emission reduction targets, highlighting sustainability achievements.

Concerns

  • The full ramp-up timeline for the Atali greenfield project has been pushed from Q1 FY26 commercialization to the end of FY26.

  • The Ganesh Polychem business experienced a slowdown in demand and a 3-4 month facility shutdown for upgrades, impacting Q4 FY25 and Q1 FY26 numbers.

  • Management acknowledged that CDMO revenue can be volatile and lumpy due to large volume customers buying at certain periods, despite expecting sustainability.

Key financials

2 periods

Q4 FY25

  • Revenue
    ₹564 Cr
    YoY +11%
  • EBITDA
    ₹146 Cr
    YoY +24%
  • EBITDA Margin
    26%
  • PAT
    ₹88 Cr
    YoY +35%

FY25

  • Revenue
    ₹2,113 Cr
    YoY +14%
  • EBITDA
    ₹464 Cr
    YoY +20%
  • PAT
    ₹272 Cr
    YoY +26%
  • Net Cash from Operations
    ₹332 Cr

What they filed

Q1 FY27: revenue up 38.9%, net profit up 52.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue458 538 564 386 418 −9%432 −20%583 +3%536 +39%
EBITDA94 129 146 93 74 −21%102 −21%113 −23%136 +46%
Net profit55 74 88 50 28 −49%48 −35%61 −31%76 +52%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Xanthine derivatives (Q4 FY25 Turnover)
    34% Contribution to Turnover
  • API & Intermediate (Q4 FY25 Turnover)
    39% Contribution to Turnover52% Regulated Market Share38% RoW Market Share10% Non-Regulated Market Share
  • CDMO/CMO (Q4 FY25 Turnover)
    27% Contribution to Turnover61 Active Projects33 Commercial Stage Projects27 Development Stage Projects

Capital allocation

high confidence
  • Capex ₹400 Cr
    • Remainder of Atali CAPEX ₹200 Cr
    • Xanthine expansion CAPEX ₹100 Cr
    • R&D CAPEX ₹40 Cr
    • Other maintenance CAPEX
    Yes, I think FY'26, overall the CAPEX number is around Rs. 400 to 450 crores total capex that we will end up doing in FY'26. There is a remainder of current CAPEX of the Atali and then there are Xanthine expansion CAPEX which will also be spent. This year we ended up spending almost Rs. 400+ crores and next year also it will be the similar number, plus or minus 10%.
  • Debt Gross ₹400 Cr · 0.2× EBITDA
    So next year in current year, think the borrowing is likely to go up by about Rs. 100 crores to Rs. 125 crores, which would basically mean debt equity of roughly in the range of 0.23 to 0.25.
  • Dividend ₹2.5/share (final)
    In line with the strong financial results and our commitment to enhancing shareholder value, the board has declared a dividend of Rs. 2.5 per share for Q4 FY'25, the final dividend, bringing total dividend for the full year to Rs. 5 per share.
  • Liquidity Liquidity disclosed Net cash from operations remained strong at Rs. 332 crores, providing financial flexibility to reinvest in capacity expansion and R&D.
    In FY'25, our net cash from the operations remained strong at Rs. 332 crores, providing us the financial flexibility to reinvest in capacity expansion in R&D.

Guidance & targets

Profitability

  • EBITDA Growth Profitability · FY26 · High confidence 12% to 15%
    On a standalone basis, we are guiding an EBITDA growth of around 12% to 15% in FY'26 over the higher base of FY'25.

    — Rashesh Gogri

Revenue

  • CDMO/CMO Revenue Growth Revenue · FY26 · High confidence 30% to 40%
    On the back of strong manufacturing capabilities and sound R&D setup, the CDMO/CMO revenue is estimated to grow around 30% to 40% in FY'26.

    — Rashesh Gogri

  • Xanthine Revenue Potential Revenue · long term · Medium confidence ₹1,000 crore to ₹1,250 crore
    I think the range would be from Rs. 1,000 crore to Rs. 1,200 crore in any number, would be the growth area of Xanthine. I think we can go up to 1,000 to 1,250 depending on how fast we are able to get commercial and how the price is sustained for the other market.

    — Rashesh Gogri

Capacity

  • Xanthine Capacity Operationalization Capacity · Q1 FY27 · High confidence 9000 MT
    The Xanthine capacity of 9000 MT is likely to be operationalized fully by Q1 FY'27.

    — Rashesh Gogri

  • Xanthine Capacity Utilization Capacity · next 3 years · High confidence 80%-90%
    In the next 3 years, we aspire for capacity utilization of 80%-90%, with 50% sales targeted to beverages and regulated customers.

    — Rashesh Gogri

Sales Mix

  • Xanthine Sales to Beverages and Regulated Customers Sales Mix · next 3 years · High confidence 50%
    In the next 3 years, we aspire for capacity utilization of 80%-90%, with 50% sales targeted to beverages and regulated customers.

    — Rashesh Gogri

Project Timeline

  • Atali Project Full Ramp-up Project Timeline · FY26 · High confidence End of FY26

    Previously Q1 FY26 commercialization → End of FY26

    The mechanical completion is expected to finish around the end of this current quarter. It's planned to get operationalized in phases and the full ramp-up is expected by the end of this financial year.

    — Rashesh Gogri

R&D Focus

  • API & Intermediate New Molecules R&D Focus · next 3 to 5 years · High confidence Focus on new molecules with patent expiry
    For API & Intermediate segment, we are continuously working towards product innovation and focusing on new molecules with patent expiry in the next 3 to 5 years.

    — Rashesh Gogri

Debt

  • Borrowing Increase Debt · next year · High confidence ₹100-125 crores
    So next year in current year, think the borrowing is likely to go up by about Rs. 100 crores to Rs. 125 crores, which would basically mean debt equity of roughly in the range of 0.23 to 0.25.

    — Piyush Lakhani

  • Debt-Equity Ratio Debt · next year · High confidence 0.23 to 0.25

    — Piyush Lakhani

What to watch in Q1 FY26

Atali Project Operationalization Progress

Next quarter (Q1 FY26) and subsequent quarters
Current Mechanical completion expected end of Q1 FY26, full ramp-up by end of FY26
Target Phased operationalization progress and initial revenue contribution

Why it matters

Monitoring the progress of this key greenfield project is crucial for future API and CDMO growth.

The mechanical completion is expected to finish around the end of this current quarter. It's planned to get operationalized in phases and the full ramp-up is expected by the end of this financial year.

Risks & concerns

  • Atali Project Timeline Push

    medium

    The full ramp-up timeline for the Atali greenfield project has been pushed from Q1 FY26 commercialization to the end of FY26, potentially delaying revenue contribution.

    Analyst acknowledged

  • CDMO Revenue Volatility

    medium

    CDMO revenue can be volatile and lumpy due to large volume customers buying at certain periods, leading to non-linearity in quarterly numbers.

    Management acknowledged

  • Ganesh Polychem Business Impact

    medium

    A slowdown in demand and a 3-4 month facility shutdown for upgrades will impact Ganesh Polychem's numbers in Q4 FY25 and Q1 FY26.

    Management acknowledged

Q&A highlights

5 direct
CDMO Primary/Secondary Supplier Quantification Partial
We are currently not quantifying them. However, each project is important and the commercialized products are being sold as commercial products by innovator in the market. That's why, wherever we are a second source, we have represented Aarti as a viable option, creating our value proposition and allowing them to shift from their other source to us.

Analyst sought specific breakdown of supplier roles in CDMO, which management did not provide but explained their strategic approach to second sourcing.

Asked by Ahmed Madha

Atali Project Timeline and Capacity Ramp-up Direct
We would like to correct that the mechanical closure of Atali phase-I will happen by end of this current quarter. Atali being also the facility from where we will do GMP intermediates supply, we have to go through the qualification. So those things will happen over next 3-4 quarters, where we take the validation batches and conclude. So that's what we have given.

Clarified the revised timeline for Atali project commercialization and ramp-up, indicating a longer lead time than previously understood for full operationalization.

Asked by Ahmed Madha

CDMO Business Lumpiness vs. Sustainability Partial
No, they will be sustainable. The products that we have in this quarter, large products will be sustainable.

Analyst probed on the recurring nature of CDMO revenue, with management asserting sustainability for large products but later acknowledging volatility.

Asked by Deep Gandhi

EBITDA Growth vs. CDMO Growth Guidance Direct
Currently, we are on significantly high base of FY25 because we have grown over last year by almost 23%-24% on EBITDA. So, over and above, I think we should be happy with the good growth.

Analyst questioned why the overall EBITDA growth guidance (12-15%) was not higher given the strong CDMO growth guidance (30-40%), leading management to explain the high base effect and initial expenses for Atali.

Asked by Prakash Kapadia

CDMO H1 vs H2 Revenue Skew Direct
No. It will be volatile, because if we have large volume customers buying at certain period of quarter, we are helpless, we have to supply them then. But we are confident about the growth that we have anticipated. But there will be no linearity in the numbers.

Analyst observed a significant H2 skew in CDMO revenue and asked about normalization, to which management confirmed volatility due to customer buying patterns.

Asked by Neha Kharodia

Ganesh Polychem Business Outlook Direct
Yes, for the Ganesh business that we have, there have been some slowdown in overall demand and what we have done is produce a significant quantity in earlier quarter and then we are actually upgrading our facility to move to a lower cost production route of synthesis for these products and that's why we have a shutdown which is ongoing for that site, which is almost 3-4 months. That's why you will see in the current Q4 as well as Q1 of this financial year the numbers will be impacted.

Analyst inquired about the significant drop in Ganesh Polychem's EBITDA, leading to management's explanation of demand slowdown and facility shutdown for upgrades.

Asked by Neha Kharodia

Promoter Selling Direct
Different promoter groups have different appetite to and long term plans. So I think there will be minor selling here or there, but it will not affect overall control of the company or anything. So I don't expect very large change in the promoter holding.

Analyst raised a concern about recent promoter selling, and management provided reassurance that it would not impact company control.

Asked by Rakesh Banerjee

3 min read 7 chapters

Detailed narrative

Strong Financial Performance in FY25

Aarti Pharmalabs reported a landmark FY25 with robust growth across all key financial metrics. Revenue grew 14% YoY to Rs. 2,113 crores, EBITDA increased 20% YoY to Rs. 464 crores, and PAT rose 26% YoY to Rs. 272 crores. The fourth quarter also set a new record for quarterly PAT at Rs. 88 crores, marking a 35% YoY growth, with EBITDA margins expanding to 26% from 23% in Q4 FY24. Net cash from operations for FY25 remained strong at Rs. 332 crores.

Segmental Contributions and Strategic Focus

In Q4 FY25, Xanthine derivatives contributed 34% of turnover, while the API & Intermediate business recorded its highest-ever quarterly sales, accounting for 39% of total turnover. The company's strategic focus on regulated markets within API was evident, with 52% of sales in regulated markets. The CDMO/CMO segment contributed 27% of turnover, with active projects increasing to 61 (from 56 in the previous quarter), including 33 at the commercial stage and 27 in development.

Capacity Expansion and Project Timelines

The Xanthine derivative capacity expansion to 9,000 metric tons is progressing as planned, with phased commissioning estimated in H2 FY26 and full operationalization by Q1 FY27. The greenfield project at Atali is nearing mechanical completion by the end of the current quarter (Q1 FY26), with phased operationalization and full ramp-up anticipated by the end of FY26. This project will add 450 KL of additional capacity, bringing the total capacity to over 1,500 KL.

FY26 Outlook and Growth Drivers

For FY26, the company guides for an EBITDA growth of 12-15% on a standalone basis, supported by higher-margin products, improved process efficiencies, and volume growth. The CDMO/CMO segment is projected to grow 30-40% in FY26, driven by a strong pipeline of 60 products and 21 customers. The company aims for 80-90% utilization of Xanthine capacity within three years, targeting Rs. 1,000-1,250 crores in revenue from this segment.

Capital Expenditure and Debt Profile

Aarti Pharmalabs spent over Rs. 400 crores on CAPEX in FY25 and plans a similar spend of Rs. 400-450 crores in FY26. This includes approximately Rs. 200 crores for the remaining Atali CAPEX and over Rs. 100 crores for Xanthine expansion, along with maintenance and R&D CAPEX (Rs. 40 crores annually for R&D). Total borrowings are currently over Rs. 400 crores, expected to increase by Rs. 100-125 crores in FY26, maintaining a debt-equity ratio of 0.23-0.25.

Sustainability Achievements

The company achieved an EcoVadis Gold Rating, placing it among the top 5% globally for sustainability. It also secured SBTi approval for GHG emission reduction targets across all three scopes, becoming the sixth Indian Pharma CDMO player to do so. These achievements underscore the company's commitment to environmental and social governance.

Ganesh Polychem Business Update

The Ganesh Polychem business experienced a slowdown in overall demand and underwent a 3-4 month facility shutdown for upgrades aimed at achieving a lower-cost production route. This is expected to impact the business's numbers in Q4 FY25 and Q1 FY26. Management anticipates normalization of numbers once the upgraded facility becomes operational.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls